Publika - Scientific publications from Oslo University Hospital

RSS feed RSS

Publications (original articles or review articles) published in 2024 from OUS - Dept. of Gastroenterology (Div Medicine)

11 publications found

Anisdahl K, Lirhus SS, Medhus AW, Moum B, Melberg HO, Høivik ML (2024)
Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study
Dig Liver Dis (in press)
DOI 10.1016/j.dld.2024.02.002, PubMed 38433021

Druckrey-Fiskaaen KT, Vold JH, Madebo T, Midgard H, Dalgard O, Leiva RA, Fadnes LT, INTRO-HCV Study Group (2024)
Liver stiffness and associated risk factors among people with a history of injecting drugs: a prospective cohort study
Subst Abuse Treat Prev Policy, 19 (1), 21
DOI 10.1186/s13011-024-00603-z, PubMed 38532435

Fejrskov A, Füchtbauer JD, Davíðsdóttir LG, Halfvarson J, Høivik ML, Jensen MD, Mortensen JH, Nielsen LN, Rejler M, Repsilber D, Söderholm JD, Aalykke C, Andersen V, Christensen R, Kjeldsen J (2024)
Novel biomarker profiles to improve individual diagnosis and prognosis in patients with suspected inflammatory bowel disease: protocol for the Nordic inception cohort study (NORDTREAT)
BMJ Open, 14 (5), e083144
DOI 10.1136/bmjopen-2023-083144, PubMed 38754881

Malme KB, Stene-Johansen K, Klundby I, Backe Ø, Foshaug T, Greve MH, Pihl CM, Finbråten AK, Dalgard O, Midgard H (2024)
Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C Trial
Viruses, 16 (6)
DOI 10.3390/v16060858, PubMed 38932151

Maurud S, Lunde L, Moen A, Opheim R (2024)
Exploring the foundations of a digital health information service for patients with inflammatory bowel disease: a mixed method study in Gravitate-Health
BMC Gastroenterol, 24 (1), 184
DOI 10.1186/s12876-024-03272-1, PubMed 38789953

Midgard H, Malme KB, Finbråten AK, Dalgard O (2024)
Treatment completion and SVR in the context of HCV elimination: Time to let go of the reins?
Clin Infect Dis (in press)
DOI 10.1093/cid/ciae298, PubMed 38824443

Midgard H, Malme KB, Pihl CM, Berg-Pedersen RM, Tanum L, Klundby I, Haug A, Tveter I, Bjørnestad R, Olsen IC, Finbråten AK, Dalgard O (2024)
Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial
Clin Infect Dis, 78 (3), 582-590
DOI 10.1093/cid/ciad711, PubMed 37992203

Salihovic S, Nyström N, Mathisen CB, Kruse R, Olbjørn C, Andersen S, Noble AJ, Dorn-Rasmussen M, Bazov I, Perminow G, Opheim R, Detlie TE, Huppertz-Hauss G, Hedin CRH, Carlson M, Öhman L, Magnusson MK, Keita ÅV, Söderholm JD, D'Amato M, Orešič M, Wewer V, Satsangi J, Lindqvist CM, Burisch J et al. (2024)
Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease
Nat Commun, 15 (1), 4567
DOI 10.1038/s41467-024-48763-7, PubMed 38830848

Strande V, Lund C, Hagen M, Bengtson MB, Cetinkaya RB, Detlie TE, Frigstad SO, Høie O, Medhus AW, Henriksen M, Aass Holten KI, Hovde Ø, Huppertz-Hauss G, Johansen I, Olsen BC, Opheim R, Ricanek P, Torp R, Tønnessen T, Vatn S, Aabrekk TB, Høivik ML, Kristensen VA (2024)
Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort
Aliment Pharmacol Ther, 60 (3), 357-368
DOI 10.1111/apt.18097, PubMed 38837289

Wiken TH, Høivik ML, Anisdahl K, Buer L, Warren DJ, Bolstad N, Hagen M, Moum BA, Medhus AW (2024)
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study
Crohns Colitis 360, 6 (1), otae013
DOI 10.1093/crocol/otae013, PubMed 38544907

Zerouga I, Valeur J, Sommer C, Cvancarova Småstuen M, Medhus AW, Lund C, Johansen I, Cetinkaya RB, Bengtson MB, Torp R, Hovde Ø, Huppertz-Hauss G, Detlie TE, Aabrekk TB, Ricanek P, Frigstad SO, Hopstock LA, Opheim R, Kristensen VA, Høivik ML, Hauger Carlsen M, Aas AM (2024)
Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study
Scand J Gastroenterol, 59 (6), 652-660
DOI 10.1080/00365521.2024.2313056, PubMed 38356408

0.12s